Axa’s Serina Therapeutics SER Stock Holding History

Axa’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,448	Closed	-$491K	–	1371
2019 Q1	$491K	Hold	3,448	–	–	﹤0.01%	1107
2018 Q4	$363K	Buy	+3,448	New	+$438K	﹤0.01%	1142

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Axa's SER Position: Q2 2019 in Review

Axa sold out of Serina Therapeutics (SER) in Q2 2019, closing a stake of 3,448 shares — an estimated $491K sold.

Axa first reported a position in SER in Q4 2018 and held it in 2 quarters. The position peaked at $491K in Q1 2019. 51 funds tracked by Wall St. Rank hold SER as of Q2 2019.

Axa reported no remaining Serina Therapeutics position as of Q2 2019 after selling out during the quarter.
Axa sold 3,448 Serina Therapeutics shares in Q2 2019, an estimated $491K.
Axa first reported a position in Serina Therapeutics in Q4 2018 and held it in 2 quarters.
Axa's Serina Therapeutics position peaked at $491K in Q1 2019.
51 funds tracked by Wall St. Rank held Serina Therapeutics as of Q2 2019.

Based on Axa's 13F filing for Q2 2019, filed 13 Aug 2019.